Keywords : Bile duct cancer, cancer
This report provides data on the therapeutic development for Bile Duct Cancer (Cholangiocarcinoma), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bile Duct Cancer (Cholangiocarcinoma) . 'Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H1 2012' is built using data and information sourced from Global Industries Direct’s p...
More »
Search ReportLinker
The Largest Collection of Market Research Reports
» 1.2 Million Industry Reports
» 450,000 Company Profiles
» 850,000 Market Briefings
» 40,000 Country Guides
From +200,000 authoritative sources
This report provides data on the therapeutic development for Bile Duct Cancer (Cholangiocarcinoma), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bile Duct Cancer (Cholangiocarcinoma) . 'Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H1 2012' is built using data and information sourced from Global Industries Direct’s proprietary databases, Firms /University websites, SEC filings, investor presentations and featured press releases from firm /university sites and market -specific third party sources, put together by Global Industries Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope of the Research
- A snapshot of the global therapeutic scenario for Bile Duct Cancer (Cholangiocarcinoma) .
- A review of the Bile Duct Cancer (Cholangiocarcinoma) products under development by industry players and universities/research institutes based on information derived from industry player and market -specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Bile Duct Cancer (Cholangiocarcinoma) pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage new product development featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Bile Duct Cancer (Cholangiocarcinoma) .
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and take over s effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Bile Duct Cancer (Cholangiocarcinoma) pipeline depth and focus of Bile Duct Cancer (Cholangiocarcinoma) therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and grow business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Global Pathology Industry
Table of Contents
Data table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global March kets Direct Report Coverage 8
Bile Duct Cancer (Cholangiocarcinoma) Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Bile Duct Cancer (Cholangiocarcinoma) 10
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics under Development by Firms 12
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics under Investigation by Universities/Institutes 14
Late Stage Products 20
Comparative Analysis 20
Mid Clinical Stage Products 21
Comparative Analysis 21
Early Clinical Stage Products 22
Comparative Analysis 22
Discovery and Pre-Clinical Stage Products 23
Comparative Analysis 23
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics – Products under Development by Firms 24
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics – Products under Investigation by Universities/Institutes 25
Companies Involved in Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Development 31
AstraZeneca PLC 31
November artis AG 32
Pfizer Inc. 33
Karo Bio 34
March shall Edwards, Inc. 35
Provecs Medical GmbH 36
Mebiopharm Co., Ltd. 37
Bile Duct Cancer (Cholangiocarcinoma) – Therapeutics Assessment 38
Assessment by Monotherapy Products 38
Assessment by Combination Products 39
Assessment by Route of Administration 40
Assessment by Molecule Type 42
Drug Profiles 45
Immunalon - Drug Profile 45
ARRY-162 - Drug Profile 47
Triphendiol - Drug Profile 49
OTS102 - Drug Profile 50
Gemcitabine + Cisplatin - Drug Profile 51
Chloroquine - Drug Profile 52
Tarceva - Drug Profile 53
Oxaliplatin + Capecitabine + Sorafenib - Drug Profile 55
Erlotinib + Gemox - Drug Profile 57
Irinotecan + Oxaliplatin - Drug Profile 59
Capecitabine + Epirubicin + Carboplatin - Drug Profile 60
Gemcitabine + Radiation Therapy - Drug Profile 62
Stakel Mediated VTP Therapy - Drug Profile 64
Gemcitabine - Drug Profile 65
BAY 43-9006 - Drug Profile 66
Panitumumab + Gemcitabine + Oxaliplatin - Drug Profile 67
mFOLFOX6 + Bevacizumab - Drug Profile 69
Sunitinib - Drug Profile 71
Capecitabine - Drug Profile 72
AZD6244 - Drug Profile 73
Foscan - Drug Profile 74
Gemcitabine + Capecitabine - Drug Profile 75
Erlotinib + Gemcitabine + Oxaliplatin - Drug Profile 76
Carcinoembryonic Antigen RNA-Pulsed DC Cancer Vaccine - Drug Profile 78
Bosutinib + Capecitabine - Drug Profile 80
Gemcitabine + Cisplatin - Drug Profile 82
Davanat + 5-Fluorouracil - Drug Profile 83
Dolastatin 10 - Drug Profile 85
Capecitabine + Gemcitabine + Radiation Therapy - Drug Profile 86
Herceptin - Drug Profile 88
Gemcitabine + Capecitabine - Drug Profile 89
Gemcitabine + Oxaliplatin + Sorafenib - Drug Profile 90
Zactima + Gemzar - Drug Profile 91
Tumor Infiltrating Lymphocytes + Cyclophosphamide + Fludarabine + Aldesleukin - Drug Profile 93
Gemcitabine + Cisplatin + Sorafenib - Drug Profile 95
Gemcitabine + 5-Fluorouracil + Radiation Therapy - Drug Profile 96
Gemcitabine + Cisplatin + S-1 - Drug Profile 98
Gemcitabine - Drug Profile 100
Gemcitabine + Sorafenib - Drug Profile 101
S-1 + Photodynamic Therapy - Drug Profile 102
S-1 + Cisplatin - Drug Profile 103
Gemcitabine + Irinotecan + Panitumumab - Drug Profile 105
Gemcitabine - Drug Profile 107
Gemzar + Taxotere - Drug Profile 108
Eloxatin + Xeloda - Drug Profile 109
Gemcitabine + Docetaxel + 5-Fluorouracil + Radiation Therapy - Drug Profile 110
S-1 + Gemcitabine - Drug Profile 112
Cancer Specific Antigen-Derived Peptide Vaccine + Gemcitabine - Drug Profile 113
TS-1 + Gemcitabine - Drug Profile 114
Capecitabine + Oxaliplatin - Drug Profile 115
RAD001 - Drug Profile 116
Gemcitabine + Oxaliplatin + Capecitabine - Drug Profile 117
GEMOX - Drug Profile 118
Gemcitabine + Cisplatin - Drug Profile 119
HLA-A 2402 Restricted A2691N Peptide + D0006 Peptide + F2861 Peptide + Montanide ISA-51 - Drug Profile 120
Gemcitabine + Radiation Therapy - Drug Profile 121
Gemcitabine + Cisplatin - Drug Profile 122
Gemcitabine + Cisplatin - Drug Profile 123
S-1 - Drug Profile 124
TS-1 - Drug Profile 125
Gemcitabine + Radiation Therapy - Drug Profile 126
Gemcitabine - Drug Profile 127
Irinotecan + Gemcitabine - Drug Profile 128
Gemcitabine + TS-1 - Drug Profile 129
Gemcitabine + Cisplatin - Drug Profile 130
Gemcitabine + S-1 - Drug Profile 131
Cisplatin - Drug Profile 132
Epirubicin + Carboplatin + Capecitabine - Drug Profile 133
mFOLFOX - Drug Profile 135
Gemox - Drug Profile 136
UFT + Leucovorin - Drug Profile 137
Gemcitabine + S-1 - Drug Profile 140
Gemcitabine - Drug Profile 141
Glivec + 5-Fluorouracil + Leucovorin - Drug Profile 142
Fludarabine + Cyclophosphamide + CD8+ Enriched TIL + Aldesleukin - Drug Profile 144
Gecitabine + Cisplatin + S-1 - Drug Profile 146
SOX - Drug Profile 148
Gemcitabine - Drug Profile 149
Gemcitabine + Oxaliplatin + Capecitabine + Bevacizumab - Drug Profile 150
Gemcitabine + Oxaliplatin + Capecitabine + Panitumumab - Drug Profile 152
5-Fluorouracil + Leucovorin + Oxaliplatin - Drug Profile 154
Cisplatin + Fluorouracil + Radiation Therapy - Drug Profile 156
Gemcitabine + TS-1 - Drug Profile 157
Gemcitabine + Capecitabine - Drug Profile 158
Gemcitabine + Oxaliplatin - Drug Profile 160
Porfimer - Drug Profile 161
Gemcitabine - Drug Profile 162
Cetuximab + Gemcitabine + Oxaliplatin - Drug Profile 163
Modified FOLFOX6 + AZD2171 - Drug Profile 164
Docetaxel + Oxaliplatin - Drug Profile 166
Cisplatin + Gemcitabine + Selumetinib - Drug Profile 167
KB9520 - Drug Profile 168
MBP-Y005 - Drug Profile 169
S-1 + Oxaliplatin - Drug Profile 170
Gemcitabine - Drug Profile 172
S-1 - Drug Profile 173
ABT-888 + Cisplatin + Gemcitabine Hydrochloride - Drug Profile 174
GEMOX + Cetuximab - Drug Profile 176
Cisplatin + Gemcitabine + Panitumumab - Drug Profile 178
Gemcitabine + Cisplatin + S-1 - Drug Profile 179
Gemcitabine + Cisplatin - Drug Profile 180
Gemcitabine + Cisplatin + Carboplatin + Capecitabine + 5-Fluorouracil + Radiation Therapy - Drug Profile 181
Gemox 85 - Drug Profile 183
Oxaliplatin + Gemcitabine + Radiation Therapy - Drug Profile 184
WT1 Peptide Vaccination + Gemcitabine + Cisplatin - Drug Profile 185
Gemcitabine + Cisplatin + S-1 - Drug Profile 186
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics – Drug Profile Updates 188
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics – Discontinued Products 191
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics - Dormant Products 192
Bile Duct Cancer (Cholangiocarcinoma) – Product Development Milestones 196
Featured News & Press Releases 196
Appendix 197
Methodology 197
Coverage 197
Secondary Research 197
Primary Research 197
Expert Panel Validation 197
Contact Us 198
Disclaimer 198
List of Tables
Number of Products Under Development for Bile Duct Cancer (Cholangiocarcinoma), H1 2012 17
Products under Development for Bile Duct Cancer (Cholangiocarcinoma) – Comparative Analysis, H1 2012 18
Number of Products under Development by Firms, H1 2012 20
Number of Products under Investigation by Universities/Institutes, H1 2012 22
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..1) 23
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..2) 24
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..3) 25
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..4) 26
Comparative Analysis by Late Stage Development, H1 2012 27
Comparative Analysis by Mid Clinical Stage Development, H1 2012 28
Comparative Analysis by Early Clinical Stage Development, H1 2012 29
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012 30
Products under Development by Firms, H1 2012 31
Products under Investigation by Universities/Institutes, H1 2012 32
Products under Investigation by Universities/Institutes, H1 2012 (Contd..1) 33
Products under Investigation by Universities/Institutes, H1 2012 (Contd..2) 34
Products under Investigation by Universities/Institutes, H1 2012 (Contd..3) 35
Products under Investigation by Universities/Institutes, H1 2012 (Contd..4) 36
Products under Investigation by Universities/Institutes, H1 2012 (Contd..5) 37
AstraZeneca PLC, H1 2012 38
November artis AG, H1 2012 39
Pfizer Inc., H1 2012 40
Karo Bio, H1 2012 41
March shall Edwards, Inc., H1 2012 42
Provecs Medical GmbH, H1 2012 43
Mebiopharm Co., Ltd., H1 2012 44
Assessment by Monotherapy Products, H1 2012 45
Assessment by Combination Products, H1 2012 46
Assessment by Stage and Route of Administration, H1 2012 48
Assessment by Stage and Molecule Type, H1 2012 51
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics – Drug Profile Updates 195
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics – Discontinued Products 198
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics – Dormant Products 199
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics – Dormant Products (Contd..1) 200
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics – Dormant Products (Contd..2) 201
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics – Dormant Products (Contd..3) 202
List of Figures
Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma), H1 2012 17
Products under Development for Bile Duct Cancer (Cholangiocarcinoma) – Comparative Analysis, H1 2012 18
Products under Development by Firms, H1 2012 19
Products under Investigation by Universities/Institutes, H1 2012 21
Late Stage Products, H1 2012 27
Mid Clinical Stage Products, H1 2012 28
Early Clinical Stage Products, H1 2012 29
Discovery and Pre-Clinical Stage Products, H1 2012 30
Assessment by Monotherapy Products, H1 2012 45
Assessment by Combination Products, H1 2012 46
Assessment by Route of Administration, H1 2012 47
Assessment by Stage and Route of Administration, H1 2012 48
Assessment by Molecule Type, H1 2012 49
Assessment by Stage and Molecule Type, H1 2012 50
